Skip to content
drillr.ai
Sign up

688278.SH

Xiamen Amoytop Biotech Co. Ltd.

SSE · Healthcare · Biotechnology · CN

CNY 59.47
−3.89%
Ask drillr

  • Sep 13, 2026, 17:20 UTC

    Four Shanghai-listed companies — Tebao Biology, Roborock, Espressif Systems and APT Medical — had repurchased 606 million, 318 million, 316 million and 300 million yuan of shares respectively as of September 11, 2026.

    Source:

  • Sep 11, 2026, 19:38 UTC

    Sun Li, chairman of Xiamen Amoytop Biotech, disclosed that the company's 2025 revenue was 3.696 billion yuan and net profit attributable to shareholders was about 1.031 billion yuan, and said that in the first half of 2026 revenue grew more than 20% and net profit grew at a double-digit rate.

    Source:

  • Sep 11, 2026, 10:43 UTC

    Amoytop Biotech announced it plans to subscribe, as a limited partner using its own funds of RMB 100 million, for a stake in Tianjin Lisixing Shen Equity Investment Partnership (Limited Partnership), a fund with a target total subscribed capital of no less than RMB 3 billion that invests in early- and mid-stage non-listed companies in AI-related fields.

    Source:

  • Sep 1, 2026, 08:41 UTC

    Amoytop Biotech disclosed that as of August 31, 2026, its second buyback plan of 2026 had repurchased 7,381,464 shares, representing 1.81% of total share capital, for a cumulative amount of 407 million yuan, with the buyback price ranging from 52.62 to 57.20 yuan per share.

    Source:

  • Aug 18, 2026, 11:08 UTC

    Amoytop Biotech announced its 2026 first-half results: net profit of 477 million yuan, up 11.37% year-on-year.

    Source:

  • Jul 6, 2026, 20:05 UTC

    Aligos Therapeutics received a $25M upfront payment from an exclusive license deal with Xiamen Amoytop Biotech for pevifoscorvir sodium in Greater China for chronic hepatitis B virus infection.

    Source: